Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Onvapegleukin alfa by Ascendis Pharma for Ovarian Cancer: Likelihood of Approval
Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Ovarian Cancer. According to GlobalData,...
Onvapegleukin alfa by Ascendis Pharma for Small-Cell Lung Cancer: Likelihood of Approval
Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Small-Cell Lung Cancer. According to...
Onvapegleukin alfa by Ascendis Pharma for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer....
Palopegteriparatide by Ascendis Pharma for Hypoparathyroidism: Likelihood of Approval
Palopegteriparatide is under clinical development by Ascendis Pharma and currently in Pre-Registration for Hypoparathyroidism. According to GlobalData, Pre-Registration drugs for...
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TransCon IL-2 beta/gamma?
TransCon IL-2 beta/gamma is a recombinant protein commercialized by Ascendis Pharma, with a leading Phase II program in Cervical Cancer....
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TransCon CNP?
TransCon CNP is a synthetic peptide commercialized by Ascendis Pharma, with a leading Phase III program in Achondroplasia. According to...
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TC-TLR7/8?
TC-TLR7/8 is a small molecule commercialized by Ascendis Pharma, with a leading Phase II program in Vaginal Cancer. According to...